You are here:

lacosamide (Vimpat)

Advice

Following an abbreviated submission:

lacosamide (Vimpat®) is accepted for restricted use within NHS Scotland.

Indication under review: as adjunctive therapy in the treatment of partial-onset seizures with or without secondary generalisation in adolescents and children from 4 years of age with epilepsy.

SMC restriction: patients with refractory epilepsy. Treatment should be initiated by physicians who have appropriate experience in the treatment of epilepsy.

SMC has previously accepted lacosamide for restricted use as adjunctive therapy in the treatment of partial-onset seizures with or without secondary generalisation in patients with epilepsy aged 16 years and older.

Drug Details

Drug Name: lacosamide (Vimpat)
SMC Drug ID: 1301/18
Manufacturer: UCB Pharma Ltd
Indication: As adjunctive therapy in the treatment of partial-onset seizures with or without secondary generalisation in adolescents and children from 4 years of age with epilepsy.
BNF Category:
Submission Type: Abbreviated Submission
Status: Restricted
Date Advice Published: 12 February 2018

Back